160 related articles for article (PubMed ID: 17022050)
1. Biochemical markers of bone turnover in diagnosis of myeloma bone disease.
Dizdar O; Barista I; Kalyoncu U; Karadag O; Hascelik G; Cila A; Pinar A; Celik I; Kars A; Tekuzman G
Am J Hematol; 2007 Mar; 82(3):185-91. PubMed ID: 17022050
[TBL] [Abstract][Full Text] [Related]
2. Biochemical markers of bone disease in asymptomatic early stage multiple myeloma. A study on their role in identifying high risk patients.
Corso A; Arcaini L; Mangiacavalli S; Astori C; Orlandi E; Lorenzi A; Passamonti F; Klersy C; Pascutto C; Canevari-Sciorati A; Lazzarino M
Haematologica; 2001 Apr; 86(4):394-8. PubMed ID: 11325645
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of urinary pyridinium crosslinks and their derivatives in multiple myeloma.
Samani KK; Brazier M; Mathiot C; Kamel S; Jamart J; Jaubert J; Blanc M; Azaïs I; Facon T; Leleu X
Ann Hematol; 2005 Jan; 84(1):19-24. PubMed ID: 15338198
[TBL] [Abstract][Full Text] [Related]
4. A comparison of methods for measuring serum and urinary markers of bone metabolism in cats.
DeLaurier A; Jackson B; Pfeiffer D; Ingham K; Horton MA; Price JS
Res Vet Sci; 2004 Aug; 77(1):29-39. PubMed ID: 15120950
[TBL] [Abstract][Full Text] [Related]
5. Abnormal bone remodelling and increased levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) in Waldenström macroglobulinaemia.
Terpos E; Anagnostopoulos A; Kastritis E; Bamias A; Tsionos K; Dimopoulos MA
Br J Haematol; 2006 May; 133(3):301-4. PubMed ID: 16643432
[TBL] [Abstract][Full Text] [Related]
6. First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma.
Tosi P; Zamagni E; Cellini C; Parente R; Cangini D; Tacchetti P; Perrone G; Ceccolini M; Boni P; Tura S; Baccarani M; Cavo M
Eur J Haematol; 2006 May; 76(5):399-404. PubMed ID: 16480429
[TBL] [Abstract][Full Text] [Related]
7. Significance of serum CrossLaps as a predictor of changes in bone mineral density during estrogen replacement therapy; comparison with serum carboxyterminal telopeptide of type I collagen and urinary deoxypyridinoline.
Okabe R; Inaba M; Nakatsuka K; Miki T; Naka H; Moriguchi A; Nishizawa Y
J Bone Miner Metab; 2004; 22(2):127-31. PubMed ID: 14999523
[TBL] [Abstract][Full Text] [Related]
8. Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1alpha and MIP-1beta correlates with lytic bone lesions in patients with multiple myeloma.
Hashimoto T; Abe M; Oshima T; Shibata H; Ozaki S; Inoue D; Matsumoto T
Br J Haematol; 2004 Apr; 125(1):38-41. PubMed ID: 15015966
[TBL] [Abstract][Full Text] [Related]
9. Serum bone sialoprotein as a marker of tumour burden and neoplastic bone involvement and as a prognostic factor in multiple myeloma.
Woitge HW; Pecherstorfer M; Horn E; Keck AV; Diel IJ; Bayer P; Ludwig H; Ziegler R; Seibel MJ
Br J Cancer; 2001 Feb; 84(3):344-51. PubMed ID: 11161399
[TBL] [Abstract][Full Text] [Related]
10. Correlation of serum collagen I carboxyterminal telopeptide concentrations with cutaneous and pulmonary involvement in systemic sclerosis.
Allanore Y; Borderie D; Lemaréchal H; Cherruau B; Ekindjian OG; Kahan A
J Rheumatol; 2003 Jan; 30(1):68-73. PubMed ID: 12508392
[TBL] [Abstract][Full Text] [Related]
11. Relationship between serum levels of vascular endothelial growth factor, hepatocyte growth factor and matrix metalloproteinase-9 with biochemical markers of bone disease in multiple myeloma.
Alexandrakis MG; Sfiridaki A; Miyakis S; Pappa C; Kandidaki E; Alegakis A; Margioris AN
Clin Chim Acta; 2007 Apr; 379(1-2):31-5. PubMed ID: 17234170
[TBL] [Abstract][Full Text] [Related]
12. The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer.
Pollmann D; Siepmann S; Geppert R; Wernecke KD; Possinger K; Lüftner D
Anticancer Res; 2007; 27(4A):1853-62. PubMed ID: 17649784
[TBL] [Abstract][Full Text] [Related]
13. Serum markers of bone turnover in children and adolescents with classic galactosemia.
Gajewska J; Ambroszkiewicz J; Radomyska B; Chełchowska M; Ołtarzewski M; Laskowska-Klita T; Milanowski A
Adv Med Sci; 2008; 53(2):214-20. PubMed ID: 18650146
[TBL] [Abstract][Full Text] [Related]
14. Bone marrow plasma macrophage inflammatory protein protein-1 alpha(MIP-1 alpha) and sclerostin in multiple myeloma: relationship with bone disease and clinical characteristics.
Wang XT; He YC; Zhou SY; Jiang JZ; Huang YM; Liang YZ; Lai YR
Leuk Res; 2014 May; 38(5):525-31. PubMed ID: 24656650
[TBL] [Abstract][Full Text] [Related]
15. Markers of bone resorption--measurement in serum, plasma or urine?
Huber F; Traber L; Roth HJ; Heckel V; Schmidt-Gayk H
Clin Lab; 2003; 49(5-6):203-7. PubMed ID: 15285175
[TBL] [Abstract][Full Text] [Related]
16. Biochemical markers of bone turnover in percutaneous vertebroplasty for osteoporotic compression fracture.
Komemushi A; Tanigawa N; Kariya S; Kojima H; Shomura Y; Tokuda T; Nomura M; Terada J; Kamata M; Sawada S
Cardiovasc Intervent Radiol; 2008; 31(2):332-5. PubMed ID: 18074174
[TBL] [Abstract][Full Text] [Related]
17. Osteopontin might be involved in bone remodelling rather than in inflammation in ankylosing spondylitis.
Choi ST; Kim JH; Kang EJ; Lee SW; Park MC; Park YB; Lee SK
Rheumatology (Oxford); 2008 Dec; 47(12):1775-9. PubMed ID: 18854347
[TBL] [Abstract][Full Text] [Related]
18. [Contribution to the evaluation of serum levels of selected biological parameters in monoclonal gammopathy of undetermined significance and in individual clinical stages of multiple myeloma].
Scudla V; Petrová P; Minarík J; Pika T; Budíková M; Bacovský J; Repovský S
Vnitr Lek; 2010 Jun; 56(6):591-601. PubMed ID: 20681472
[TBL] [Abstract][Full Text] [Related]
19. Role of type I collagen C telopeptide, bone-specific alkaline phosphatase and osteocalcin in the assessment of bone status in postmenopausal women.
Trento LK; Pietropolli A; Ticconi C; Gravotta E; De Martino MU; Fabbri A; Piccione E
J Obstet Gynaecol Res; 2009 Feb; 35(1):152-9. PubMed ID: 19215563
[TBL] [Abstract][Full Text] [Related]
20. Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity.
Alexandrakis MG; Passam FH; Sfiridaki A; Kandidaki E; Roussou P; Kyriakou DS
Am J Hematol; 2003 Apr; 72(4):229-33. PubMed ID: 12666132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
